Fintel reports that on June 28, 2024, Rodman & Renshaw initiated coverage of Leap Therapeutics (NasdaqCM:LPTX) with a Buy recommendation.
Analyst Price Forecast Suggests 491.96% Upside
As of June 12, 2024, the average one-year price target for Leap Therapeutics is 11.60. The forecasts range from a low of 5.56 to a high of $16.80. The average price target represents an increase of 491.96% from its latest reported closing price of 1.96.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Leap Therapeutics is 1MM, an increase of 262.67%. The projected annual non-GAAP EPS is -0.58.
What is the Fund Sentiment?
There are 67 funds or institutions reporting positions in Leap Therapeutics. This is an increase of 17 owner(s) or 34.00% in the last quarter. Average portfolio weight of all funds dedicated to LPTX is 0.03%, an increase of 9.72%. Total shares owned by institutions increased in the last three months by 26.39% to 8,734K shares. 
The put/call ratio of LPTX is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 1,172K shares representing 3.06% ownership of the company. No change in the last quarter.
Rock Springs Capital Management holds 912K shares representing 2.38% ownership of the company. In its prior filing, the firm reported owning 833K shares , representing an increase of 8.66%. The firm decreased its portfolio allocation in LPTX by 27.54% over the last quarter.
Citadel Advisors holds 711K shares representing 1.86% ownership of the company. In its prior filing, the firm reported owning 683K shares , representing an increase of 4.02%. The firm decreased its portfolio allocation in LPTX by 43.61% over the last quarter.
Balyasny Asset Management holds 671K shares representing 1.75% ownership of the company.
Samsara BioCapital holds 669K shares representing 1.75% ownership of the company. No change in the last quarter.
Leap Therapeutics Background Information
(This description is provided by the company.)
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
